Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Piflufolastat F-18

FDA-approved product (solution, intravenous), marketed as Pylarify, Pylarify Truvu.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Piflufolastat F-18
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Computed tomography
  • Metastatic prostate cancer
  • Prostate adenocarcinoma
  • Prostate cancer
  • Prostate neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other diagnostic radiopharmaceuticals for tumour detection
FDA pharmacologic class
Radioactive Diagnostic Agent FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA44.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Piflufolastat F-18 in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Piflufolastat F-18 with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Integrated 18F-labelled PSMA Project

    NCT02691169 · start 2016-04

    Registered record
    Registry ID
    NCT02691169
    Conditions
    Prostate Cancer
    Interventions
    18F-DCFPyL
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2016-04
    Completion
    2017-12
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Intervention18F-DCFPyL
    PhaseEarly phase 1
    Registry statusUnknown

  • Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy

    NCT02523924 · start 2015-06-02

    Registered record
    Registry ID
    NCT02523924
    Conditions
    Adenocarcinoma of the Prostate
    Interventions
    18F-DCFPyL
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-06-02
    Completion
    2019-03-04
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenocarcinoma of the Prostate
    Intervention18F-DCFPyL
    PhaseNot applicable
    Registry statusCompleted

  • Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate Cancer

    NCT02151760 · start 2014-05

    Registered record
    Registry ID
    NCT02151760
    Conditions
    Metastatic Prostate Cancer
    Interventions
    18F-DCFPyL
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-05
    Completion
    2020-04
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Prostate Cancer
    Intervention18F-DCFPyL
    PhasePhase 1
    Registry statusCompleted

  • F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer

    NCT03501940

    Registered record
    Registry ID
    NCT03501940
    Conditions
    Prostate Adenocarcinoma; PSA Level Greater Than 0.2; PSA Level Greater Than or Equal to Two; PSA Progression; Recurrent Prostate Carcinoma
    Interventions
    Computed Tomography; Fluorine F 18 DCFPyL; Laboratory Biomarker Analysis; Positron Emission Tomography
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma; PSA Level Greater Than 0.2; PSA Level Greater Than or Equal to Two; PSA Progression +1 more
    InterventionComputed Tomography; Fluorine F 18 DCFPyL; Laboratory Biomarker Analysis; Positron Emission Tomography
    PhaseNot recorded
    Registry statusNo longer available

  • 18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer

    NCT04809584

    Registered record
    Registry ID
    NCT04809584
    Conditions
    Prostate Cancer
    Interventions
    F18-DCFPyL; Gadolinium; Positron emission tomography (PET)/Magnetic Resonance Imaging (MRI) Scan
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    Approved for marketing
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionF18-DCFPyL; Gadolinium; Positron emission tomography (PET)/Magnetic Resonance Imaging (MRI) Scan
    PhaseNot recorded
    Registry statusApproved for marketing